Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II preoperative window study of olaparib with or without cisplatin versus no treatment in operable head and neck squamous cell carcinoma
2015-005268-41Phase 2Completed
- Sponsor
- HeCOG
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of olaparib and cisplatin in head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by HeCOG. Primary endpoint: Change in tumour Ki-67 (olaparib + cisplatin vs olaparib alone). Started Mar 2016; status: completed.
02
Drugs
olaparibcisplatin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2015-005268-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005268-41.